Effects of chebulic acid on advanced glycation endproducts-induced collagen cross-links

Biological and Pharmaceutical Bulletin

Volumn 37, Issue 7, 2014, Pages 1162-1167

  Lee, Ji Young ^a   Oh, Jun Gu ^a   Kim, Jin Sook ^b   Lee, Kwang Won ^a  

^a Korea University   (South Korea)

^b Korea Institute of Oriental Medicine (KIOM)   (South Korea)

Author keywords

Advanced glycation end product; Antiglycation effect; Chebulic acid; Chelating activity; Collagen cross link; Terminalia chebula

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; AMINOGUANIDINE; ANTIOXIDANT; ASCORBIC ACID; BOVINE SERUM ALBUMIN; CHEBULIC ACID; COLLAGEN; COPPER; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG; 2,2-DIPHENYL-1-PICRYLHYDRAZYL; ACETALDEHYDE; BENZOPYRAN DERIVATIVE; BIPHENYL DERIVATIVE; CROSS LINKING REAGENT; GLYCOLALDEHYDE; PICRIC ACID; SCAVENGER;

ANTIOXIDANT ACTIVITY; ARTICLE; CHELATION; CONTROLLED STUDY; IC 50; IN VITRO STUDY; OXIDATION; PROTEIN CROSS LINKING; TERMINALIA CHEBULA; ANALOGS AND DERIVATIVES; CHEMISTRY; DIABETES COMPLICATIONS; ENZYME LINKED IMMUNOSORBENT ASSAY; FRUIT; ISOLATION AND PURIFICATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; TERMINALIA;

ACETALDEHYDE; BENZOPYRANS; BIPHENYL COMPOUNDS; COLLAGEN; CROSS-LINKING REAGENTS; DIABETES COMPLICATIONS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FREE RADICAL SCAVENGERS; FRUIT; GLYCOSYLATION END PRODUCTS, ADVANCED; PICRATES; SERUM ALBUMIN, BOVINE; TERMINALIA;

EID: 84904654596     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b14-00034     Document Type: Article

References (24)

1. Bucala CA. Advanced glycosylation: Chemistry, biology, and implications for diabetes and aging. Academic Press, Inc., California, 1992.
2. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med., 318, 1315-1321 (1988).
3. Sugiyama S, Miyata T, Horie K, Iida Y, Tsuyuki M, Tanaka H, Maeda K. Advanced glycation end-products in diabetic nephropathy. Nephrol. Dial. Transplant., 11 (Suppl. 5), 91-94 (1996).
4. Ahmed N. Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res. Clin. Pract., 67, 3-21 (2005).
5. Cerami A, Ulrich P. Pharmaceutical intervention of advanced glycation endproducts. Novartis Found. Symp., 235, 202-212, discussion, 212-216, 217-220 (2001).
6. Thomas MC, Baynes JW, Thorpe SR, Cooper ME. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr. Drug Targets, 6, 453-474 (2005).
7. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein crosslinking. Science, 232, 1629-1632 (1986).
8. Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch. Biochem. Biophys., 419, 31-40 (2003).
9. Vasan S, Foiles PG, Founds HW. Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links. Expert Opin. Investig. Drugs, 10, 1977-1987 (2001).
10. Vaitkevicius PV, Lane M, Spurgeon H, Ingram DK, Roth GS, Egan JJ, Vasan S, Wagle DR, Ulrich P, Brines M, Wuerth JP, Cerami A, Lakatta EG. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc. Natl. Acad. Sci. U.S.A., 98, 1171-1175 (2001).
11. Wolffenbuttel BHR, Boulanger CM, Crijns FRL, Huijberts MSP, Poitevin P, Swennen GNM, Vasan S, Egan JJ, Ulrich P, Cerami A, Levy BI. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc. Natl. Acad. Sci. U.S.A., 95, 4630-4634 (1998).
12. Hartag JW, Willemsen S, van Veldhuisen DJ, Posma JL, van Wijk LM, Hummel YM, Hillege HL, Voovs AA, BENEFICIAL investigators. Effect of alagebrium, an advanced glycation endproduct breaker, on exercise tolerence and cardiac funtion in patient with chronic heart failure. Eur. J. Heart Fail., 13, 899-908 (2011).
13. Tapsell LC, Hemphill I, Cobiac L, Patch CS, Sullivan DR, Fenech M, Roodenrys S, Keogh JB, Clifton PM, Williams PG, Fazio VA, Inge KE. Health benefits of herbs and spices: the past, the present, the future. Med. J. Aust., 185 (Suppl.), S4-S24 (2006).
14. Lee HS, Jung SH, Yun BS, Lee KW. Isolation of chebulic acid from Terminalia chebula RETZ. and its antioxidant effect in isolated rat hepatocytes. Arch. Toxicol., 81, 211-218 (2007).
15. Ahmad I, Mehmood Z, Mohammad F. Screening of some Indian medicinal plants for their antimicrobial properties. J. Ethnopharmacol., 62, 183-193 (1998).
16. Lee HS, Won NH, Kim KH, Lee H, Jun W, Lee KW. Antioxidant effects of aqueous extract of Terminalia chebula in vivo and in vitro. Biol. Pharm. Bull., 28, 1639-1644 (2005).
17. Lee HS, Koo YC, Suh HJ, Kim KY, Lee KW. Preventive effects of chebulic acid isolated from Terminalia chebula on advanced glycation endproduct-induced endothelial cell dysfunction. J. Ethnopharmacol., 131, 567-574 (2010).
18. Kim YS, Kim J, Kim CS, Sohn EJ, Lee YM, Jeong IH, Kim H, Jang DS, Kim JS. KIOM-79, an inhibitor of AGEs-protein crosslinking, prevents progression of nephropathy in Zucker diabetic fatty rats. Evid.-Based Compl. Alt., 2011, 1-10 (2011).
19. Laemmli U. Cleavage of structural proteins during assembly of head of bacteriophage T4. Nature, 227, 680-685 (1970).
20. Nagai R, Murray DB, Metz TO, Baynes JW. Chelation: A fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications. Diabetes, 61, 549-559 (2012).
21. Goh SY, Cooper ME. The role of advanced glycation end products in progression and complications of diabetes. J. Clin. Endocrinol. Metab., 93, 1143-1152 (2008).
22. Price DL, Rhett PM, Thorpe SR, Baynes JW. Chelating activity of advanced glycation end-product inhibitors. J. Biol. Chem., 276, 48967-48972 (2001).
23. Lee HS, Cho HY, Park KW, Kim IH, Kim JT, Nam MH, Lee KW. Inhibitory effects of Terminalia chebula extract on glycation and endothelial cell adhesion. Planta Med., 77, 1060-1067 (2011).
24. Nagai R, Nagai M, Shimasaki S, Baynes JW, Fujiwara Y. Citric acid inhibits development of cataracts, proteinuria and ketosis in streptozotocin (type 1) diabetic rats. Biochem. Biophys. Res. Commun., 393, 118-122 (2010).